NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Virinchi Board Approves ₹30 Cr Preferential Warrants Issue at ₹15/Share
Virinchi Limited's board has approved raising up to ₹30 crore via the preferential allotment of up to 2,00,00,000 convertible equity warrants at ₹15 per warrant. The fundraise constitutes approximately 17% of the company's current market cap of ₹176 crore. Promoter Viswanath Kompella will subscribe to 1.50 crore warrants, while public entity IT Peer Technologies LLC will subscribe to 50 lakh warrants. An EGM to seek shareholder approval is scheduled for December 10, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board approved a ₹30 crore fundraise via preferential convertible warrants, significantly backed by the promoter group.
ஏன் இது முக்கியம்The capital infusion represents ~17% of market cap and will inject cash into a loss-making business (TTM net profit of ₹-30 crore, debt of ₹132 crore) while signaling promoter commitment through an increased stake.
Total fundraise value: Rs. 30,00,00,000Issue price per warrant: Rs. 15Total warrants proposed: 2,00,00,000Fundraise vs Market Cap: ~17.0%Promoter post-issue holding: 47.60%
📅 குறுகிய காலம்Supportive sentiment due to promoter capital commitment priced at a slight premium (₹15) to the prevailing share price (₹14.5).
📈 நீண்ட காலம்If converted over the 18-month tenure, the ₹30 crore infusion will bolster net worth and liquidity, helping deleverage or fund healthcare/IT operations.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of existing public shareholders (public holding decreases from 60.54% to 52.40% post-conversion)
Execution and business turnaround risks given recent net losses (TTM PAT of ₹-30 crore)
👀 கவனிக்க வேண்டியவை
Track shareholder voting results from the upcoming EGM on December 10, 2026, and monitor the timeline for warrant subscription inflows and debt repayment or capex deployment.
95.13% Shareholders Approve Acquisition of Bristlecone Hospitals Division via Slump Sale
Shareholders of Virinchi Limited have approved the acquisition of the Primary and Secondary Healthcare Business Division (Bristlecone Hospitals brand) from its material subsidiary, Virinchi Health Care Private Limited. The transaction is structured as a slump sale, effectively consolidating these healthcare operations directly into the parent company. While 95.13% of the polled public votes were in favor, the total voter turnout was low at 4.89% of the total share capital. Promoters, holding 39.46% of the company, were considered interested parties and did not participate in the voting.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe healthcare business division previously held under a subsidiary is being transferred to the parent company, Virinchi Limited, through a slump sale mechanism.
ஏன் இது முக்கியம்This internal restructuring consolidates the healthcare brand and operations, which may simplify the corporate structure but also brings the operational risks of the healthcare segment directly onto the parent's balance sheet.
Votes in favor: 5,242,203Votes against: 268,626Public voter turnout: 8.08%Total shares on record: 112,707,372Transaction value: வெளியிடப்படவில்லை
📅 குறுகிய காலம்The market is likely to view this as a routine internal restructuring; immediate price impact may be limited given the lack of disclosed transaction value.
📈 நீண்ட காலம்Consolidation could streamline the 'Bundling and Unbundling' strategy for the healthcare segment, but the company must address the historical volatility in healthcare revenue seen in FY23.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction
Low public voter participation
Transaction value not disclosed in the voting result
👀 கவனிக்க வேண்டியவை
Watch for the disclosure of the transaction value (slump sale consideration) in upcoming filings to assess the impact on the parent company's debt-to-equity ratio, which currently stands at 0.28.
Virinchi to acquire Bristlecone Hospitals division for ₹100 Cr via slump sale
Virinchi Limited has announced the acquisition of the Primary and Secondary Healthcare Business Division (Bristlecone Hospitals brand) from its material subsidiary, Virinchi Health Care Private Limited (VHCPL). The transaction is valued at ₹100 Crores and will be executed as a slump sale effective April 1, 2026. The consideration will be settled by adjusting existing loans and advances provided by Virinchi Limited to the subsidiary. The target division reported a turnover of ₹82.99 Cr and a net loss of ₹33.26 Cr for FY26, indicating a significant turnaround requirement.
உச்சம் நம்பிக்கை
என்ன மாறியதுVirinchi is moving the community healthcare business from its subsidiary directly to the parent company's books to create a dedicated AI-first healthcare platform.
ஏன் இது முக்கியம்The transaction is material at ~35% of TTM revenue. While it cleans up the subsidiary's debt to the parent, it brings a loss-making unit with declining revenues directly into the listed entity's operations.
Acquisition Value: ₹100 கோடிValue vs TTM Revenue: 35.21%Target FY26 Revenue: ₹82.99 கோடிTarget FY26 Net Loss: ₹33.26 கோடிTarget FY26 Net Worth: ₹-28.11 கோடி
📅 குறுகிய காலம்The market may view the acquisition of a loss-making unit with negative net worth from a subsidiary at a ₹100 Cr valuation with caution.
📈 நீண்ட காலம்The company aims to build an AI-first healthcare platform; however, the structural decline in the acquired unit's revenue over the last three years poses a significant execution risk.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction
Acquisition of a loss-making unit
Negative net worth of the target division
Declining revenue trend in the acquired business
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results on August 12, 2026, and scrutinize the next quarterly results to see how the consolidation of this loss-making unit impacts the parent company's already stressed bottom line (TTM PAT of -₹28 Cr).
Virinchi Seeks Approval for ₹50 Cr Loan and ₹90 Cr in Related Party Transactions
Virinchi Limited has issued a postal ballot notice to seek shareholder approval for three significant financial resolutions. The company intends to provide loans or guarantees up to ₹50 crore to its subsidiary, Virinchi Health Care Private Limited (VHCPL). Furthermore, it is seeking approval for material related party transactions (RPTs) totaling ₹60 crore with VHCPL and ₹30 crore with Vivo Bio Tech Limited, a promoter group entity. The voting period for these resolutions runs from June 15, 2026, to July 14, 2026.
முக்கிய அம்சங்கள்
Proposed loan or guarantee of up to ₹50 crore to subsidiary Virinchi Health Care Private Limited for its principal business activities.Approval sought for material RPTs with VHCPL up to ₹60 crore, including ₹10 crore for services and ₹50 crore for resource transfers.Approval sought for material RPTs with promoter group entity Vivo Bio Tech Limited up to ₹30 crore.E-voting period scheduled from June 15, 2026, to July 14, 2026, with results expected by July 16, 2026.Management asserts that all proposed transactions are at arm's length and within the ordinary course of business.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results and scrutinize the terms of the ₹30 crore transaction with the promoter group entity to ensure no value leakage. Additionally, track the performance of the healthcare subsidiary to justify the ₹50 crore capital allocation.
Virinchi Ltd Allots 20 Lakh Equity Shares Following Warrant Conversion
Virinchi Limited has allotted 20,00,000 equity shares of Rs. 10 each following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 25 per share, which includes a premium of Rs. 15. The company received Rs. 3.75 crore, representing the remaining 75% of the total issue price from nine public shareholders. As a result, the company's total subscribed share capital has increased to Rs. 112.56 crore across 11.25 crore shares.
முக்கிய அம்சங்கள்
Allotment of 20,00,000 equity shares upon conversion of preferential warrants.Issue price fixed at Rs. 25 per share, including a premium of Rs. 15.Inflow of Rs. 3.75 crore representing the 75% balance payment for the warrants.Total paid-up equity capital increased to 11,25,57,372 shares of Rs. 10 each.Allotment made to 9 public category investors, including Dwight Technologies Private Limited.
👀 கவனிக்க வேண்டியவை
Investors should note the capital infusion and the resulting equity dilution. The conversion at Rs. 25 per share provides a benchmark for investor sentiment regarding the company's valuation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Virinchi FY26 Revenue Drops 7% to ₹286 Cr; Reports Consolidated Net Loss of ₹27.4 Cr
Virinchi Limited reported a challenging FY26 with consolidated revenue declining 7.19% YoY to ₹286.13 crore and a net loss of ₹27.39 crore, compared to a profit of ₹0.48 crore in FY25. The performance was severely impacted by a one-time bad-debt write-off of ₹8.43 crore from a major SaaS client and a 29.55% decline in the IDC & IT Services segment due to US visa restrictions. While the SaaS business grew 15.42% to ₹153.94 crore, the healthcare division saw a 23.2% revenue drop, though it managed a marginal EBIT turnaround to ₹0.15 crore.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue fell 7.19% YoY to ₹286.13 crore with a net loss of ₹27.39 crore.A one-time write-off of ₹8.43 crore (USD 890,530) from QC Holdings significantly hit Q4 and FY26 profitability.IDC & IT Services revenue declined 29.55% to ₹40.37 crore, resulting in an EBIT loss of ₹2.37 crore due to US visa challenges.Healthcare segment revenue dropped 23.20% to ₹79.99 crore, but achieved a marginal EBIT of ₹0.15 crore vs a loss in FY25.Promoter acquired a 49% stake in the healthcare subsidiary via fresh capital infusion in March 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company has swung into a significant consolidated loss and faces structural headwinds in its IT services segment. The stock's recovery depends on the successful turnaround of the healthcare business and the stability of the SaaS segment's recurring revenue without further write-offs.
Virinchi FY26 Results: Consolidated Revenue Down 19%, Swings to Net Loss of ₹14.33 Cr
Virinchi Limited reported a weak set of consolidated financial results for the fiscal year ended March 31, 2026. Consolidated revenue from operations declined by 18.8% YoY to ₹244.36 crore, while the company swung to a net loss of ₹14.33 crore from a profit of ₹12.61 crore in the previous year. Although the standalone entity remained profitable with a net profit of ₹13.66 crore, the consolidated performance was severely impacted by losses in subsidiary operations and high depreciation costs of ₹55.41 crore.
முக்கிய அம்சங்கள்
Consolidated revenue from operations decreased to ₹244.36 crore in FY26 from ₹301.13 crore in FY25.Reported a consolidated net loss of ₹14.33 crore compared to a net profit of ₹12.61 crore in the previous fiscal.Consolidated EPS turned negative at ₹(1.38) for the year, down from ₹1.52 in FY25.SaaS Business (US Fintech) revenue grew 15.5% YoY to ₹153.94 crore, providing a partial offset to declines in other segments.Net cash generated from operating activities fell sharply to ₹20.99 crore from ₹43.98 crore in the prior year.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company has moved from profitability to a significant consolidated loss, primarily due to underperforming subsidiaries. Monitor the SaaS segment's growth and management's plan to turn around the healthcare and IT services divisions.
Virinchi Reports FY26 Consolidated Net Loss of ₹29.98 Cr as Revenue Declines 18.8%
Virinchi Limited reported a significant downturn in its consolidated financial performance for the fiscal year ended March 31, 2026. Consolidated revenue fell by 18.8% to ₹244.36 crore compared to ₹301.13 crore in the previous year. The company swung from a net profit of ₹15.95 crore in FY25 to a substantial net loss of ₹29.98 crore in FY26. While the SaaS business remained profitable, losses in IDC & IT services and Payment & Credit services, along with high finance costs, severely impacted the bottom line.
முக்கிய அம்சங்கள்
Consolidated revenue decreased to ₹244.36 crore in FY26 from ₹301.13 crore in FY25Reported a consolidated net loss of ₹29.98 crore against a profit of ₹15.95 crore in the previous fiscalThe SaaS Business (US Fintech) was the primary revenue driver at ₹153.94 crore but saw segment results drop to ₹13.18 croreFinance costs remained high at ₹32.97 crore, further straining profitabilityThe company allotted 61.50 lakh equity shares during Q4 FY26 following the conversion of warrants
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company has moved into a significant loss-making position on a consolidated basis. The sharp decline in revenue and losses across multiple business segments suggest operational challenges that require a clear turnaround strategy.
Virinchi Limited Allots 9.10 Lakh Equity Shares on Warrant Conversion
Virinchi Limited has approved the allotment of 9,10,476 equity shares following the conversion of warrants previously issued on a preferential basis. The shares were issued at a price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% application money amounting to approximately Rs. 1.91 crore from IT Peer Technologies LLC. Consequently, the total paid-up share capital of the company has increased to Rs. 110.55 crore.
முக்கிய அம்சங்கள்
Allotment of 9,10,476 equity shares of Rs. 10 face value eachIssue price fixed at Rs. 28 per share, including a premium of Rs. 18Receipt of Rs. 1,91,19,996 representing the 75% balance payment for conversionTotal issued and subscribed share capital increased to 11,05,57,372 equity sharesAllotment made to IT Peer Technologies LLC under the Public category
👀 கவனிக்க வேண்டியவை
Investors should account for the minor equity dilution resulting from this warrant conversion. The focus should remain on the company's utilization of these funds for future growth and operational expansion.
Virinchi Ltd Allots 8.5 Lakh Equity Shares to Promoter Group on Warrant Conversion
Virinchi Limited has successfully converted 8,50,000 warrants into equity shares for Vivo Bio Tech Limited, a promoter group entity. The shares were issued at a price of Rs. 28 per share, including a premium of Rs. 18. The company received the remaining 75% application money totaling Rs. 1.78 crore. This move increases the total issued and subscribed share capital to approximately Rs. 109.65 crore across 10.96 crore shares.
முக்கிய அம்சங்கள்
Allotment of 8,50,000 equity shares of Rs. 10 face value each.Conversion price set at Rs. 28 per share, including a premium of Rs. 18.Receipt of Rs. 1,78,50,000 representing the 75% balance of the issue price.Allotment made to Vivo Bio Tech Limited, part of the Promoter Group.Post-allotment share capital stands at 10,96,46,896 equity shares.
👀 கவனிக்க வேண்டியவை
The conversion of warrants by a promoter group entity indicates long-term commitment and confidence in the company's prospects. Investors should monitor the impact of this equity dilution on earnings per share (EPS) in upcoming quarters.
Virinchi Ltd Subsidiary Stake Diluted to 51% Following •7.83 Cr Promoter Investment
Virinchi Limited's subsidiary, Virinchi Health Care Private Limited (VHPL), has allotted 52.22 lakh equity shares to promoter Viswanath Kompella for a total consideration of •7.83 crore. This transaction, executed via warrant conversion at •15 per share, has reduced Virinchi Limited's stake in the subsidiary from 100% to 51%. VHPL is a significant contributor to the group, accounting for 30.73% of the consolidated turnover in FY24-25. While the company remains a subsidiary, the substantial 49% minority interest now held by the promoter will impact future consolidated net profit attributable to shareholders.
முக்கிய அம்சங்கள்
Promoter Viswanath Kompella acquired a 49% stake in VHPL for •7.83 croreVirinchi Limited's ownership in the healthcare subsidiary diluted from 100% to 51%VHPL contributed •92.54 crore (30.73%) to consolidated revenue in FY2024-25The allotment was based on an independent enterprise valuation of •312.08 crore for VHPLA total of 52,22,000 warrants were converted into equity shares as of March 9, 2026
👀 கவனிக்க வேண்டியவை
Investors should assess if the •312 crore valuation for the healthcare business is fair and monitor how the 49% stake dilution affects the parent company's bottom line. The direct capital infusion into the subsidiary by the promoter may signal growth plans but also increases related-party involvement.
Virinchi Ltd Allots 13.15 Lakh Equity Shares to Promoter Group on Warrant Conversion
Virinchi Limited has successfully allotted 13,15,715 equity shares to Vivo Bio Tech Limited, a promoter group entity, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% application money, totaling approximately Rs. 2.76 crore, to complete the conversion. This move increases the total issued and subscribed share capital to Rs. 108.80 crore, representing 10,87,96,896 equity shares.
முக்கிய அம்சங்கள்
Allotment of 13,15,715 equity shares to Promoter Group entity Vivo Bio Tech LimitedIssue price of Rs. 28 per share including a premium of Rs. 18 per shareReceipt of Rs. 2,76,30,015 representing the final 75% payment for warrant conversionTotal paid-up share capital increased to Rs. 108,79,68,960 divided into 10.88 crore shares
👀 கவனிக்க வேண்டியவை
The conversion of warrants by a promoter group entity is a positive signal indicating long-term commitment and confidence in the company's prospects. Investors should monitor the utilization of the newly raised capital and its impact on the company's debt-to-equity ratio.
Virinchi Shareholders Approve Related Party Investment and Warrant Issue for Healthcare Subsidiary
Virinchi Limited shareholders have approved two major special resolutions through a postal ballot concluded on February 23, 2026. The resolutions facilitate investment by a related party into Virinchi Health Care Private Limited, a 100% subsidiary, and the issuance of convertible equity warrants by the same entity. Both proposals received strong support from public shareholders, with over 92% voting in favor. This move is expected to provide necessary capital for the healthcare division's operations or expansion.
முக்கிய அம்சங்கள்
Approval for related party investment in 100% subsidiary Virinchi Health Care Private LimitedIssuance of convertible equity warrants by the healthcare subsidiary approvedResolution 1 (Investment) passed with 92.7% majority representing 2,558,985 votes in favorResolution 2 (Warrants) passed with 92.61% majority representing 2,556,489 votes in favorPromoters and promoter group abstained from voting as they were interested parties
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific terms and valuation of the investment and warrants to understand the impact on the subsidiary's ownership structure. This capital infusion could be a precursor to scaling the healthcare business.
Virinchi Ltd Allots 20.7 Lakh Equity Shares to Promoter Group at Rs 28 Per Share
Virinchi Limited has successfully allotted 20,70,000 equity shares to Vivo Bio Tech Limited, a member of the Promoter Group, following the conversion of warrants. The allotment was executed at an issue price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% of the application money, totaling approximately Rs. 4.35 crore, to complete the conversion. This move increases the company's total paid-up share capital to Rs. 107.48 crore, represented by over 10.74 crore shares.
முக்கிய அம்சங்கள்
Allotment of 20,70,000 equity shares to Promoter Group entity Vivo Bio Tech LimitedConversion price set at Rs. 28 per share, including a premium of Rs. 18 per shareReceipt of Rs. 4,34,70,000 representing the final 75% payment for the warrantsTotal issued and subscribed share capital increased to 10,74,81,181 equity sharesThe transaction demonstrates promoter commitment and provides a capital infusion of over Rs. 4.3 crore
👀 கவனிக்க வேண்டியவை
Investors should view the promoter's decision to convert warrants as a positive sign of confidence in the company's future. However, one should also account for the minor equity dilution resulting from the increased share count.
Virinchi Q3 Results: Consolidated Profit Returns to ₹1.60 Cr; Standalone PAT Jumps 152% YoY
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, showing a 24.5% sequential recovery from Q2 but a 6.7% decline year-on-year. The company returned to a consolidated net profit of ₹1.60 crore, recovering from a massive ₹13.67 crore loss in the previous quarter. Standalone performance was notably stronger, with net profit rising 152% YoY to ₹8.38 crore. Despite the quarterly recovery, the company remains in a consolidated net loss of ₹11.70 crore for the nine-month period ending December 2025.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3 FY26 at ₹76.89 crore, up 24.5% QoQ but down 6.7% YoYConsolidated Net Profit of ₹1.60 crore vs a loss of ₹13.67 crore in Q2 FY26Standalone Net Profit surged to ₹8.38 crore from ₹3.32 crore in the same quarter last yearSaaS Business (US Fintech) led segment performance with ₹40.20 crore revenue and ₹8.39 crore profitHealth Care Services contributed ₹25.55 crore to revenue with a segment profit of ₹3.13 crore
👀 கவனிக்க வேண்டியவை
Investors should track the sustainability of the return to consolidated profitability and investigate the causes of the significant losses in subsidiaries that are dragging down consolidated performance relative to standalone results. The strong performance of the SaaS/Fintech segment remains the primary value driver for the company.
Virinchi Q3 FY26: Consolidated Revenue at ₹76.89 Cr, Returns to Profitability QoQ
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, marking a 24.5% recovery from the previous quarter. The company successfully returned to a consolidated net profit of ₹1.60 crore, reversing a heavy loss of ₹13.67 crore in Q2 FY26. Standalone performance was notably stronger, with net profit jumping 152% YoY to ₹8.38 crore, primarily driven by the SaaS and IT services segment. However, on a consolidated basis, both revenue and profit remain lower compared to the same quarter last year (Q3 FY25).
முக்கிய அம்சங்கள்
Consolidated Revenue stood at ₹76.89 Cr, up 24.5% QoQ but down 6.7% YoY.Returned to Consolidated Net Profit of ₹1.60 Cr vs a loss of ₹13.67 Cr in Q2 FY26.Standalone Net Profit grew 152% YoY to ₹8.38 Cr from ₹3.32 Cr.Consolidated Finance Costs remain high at ₹7.85 Cr for the quarter.SaaS Business (US Fintech) remains the primary driver of standalone profitability, contributing ₹40.20 Cr to revenue.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the turnaround in consolidated profitability and the performance of the healthcare subsidiary which appears to be dragging group margins. While the standalone IT business is robust, high consolidated finance costs remain a key risk factor to watch.
Virinchi Allots 17.14 Lakh Equity Shares to Promoter Group via Warrant Conversion
Virinchi Limited has allotted 17,14,285 equity shares to Vivo Bio Tech Limited, a member of the promoter group, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 each, including a premium of Rs. 18 per share. The company received approximately Rs. 3.60 crore, representing the remaining 75% of the application money required for the conversion. This transaction increases the company's total paid-up equity capital to Rs. 105.41 crore.
முக்கிய அம்சங்கள்
Allotment of 17,14,285 equity shares of Rs. 10 each at a premium of Rs. 18 per shareReceipt of Rs. 3,59,99,985 as the final 75% payment for warrant conversionShares allotted to Vivo Bio Tech Limited, part of the Promoter GroupTotal paid-up share capital increased to 10,54,11,181 equity shares
👀 கவனிக்க வேண்டியவை
The conversion of warrants by a promoter group entity indicates long-term commitment and confidence in the company's valuation. Investors should monitor how the fresh capital infusion is utilized for business expansion or debt reduction.
Virinchi Allots 10.5 Lakh Equity Shares Following Warrant Conversion
Virinchi Limited has successfully allotted 1,050,000 equity shares of Rs. 10 each following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 25 per share, which includes a premium of Rs. 15. The company received the remaining 75% of the application money, amounting to approximately Rs. 1.97 crore, from a public category investor. This conversion has increased the company's total paid-up share capital to approximately Rs. 103.70 crore.
முக்கிய அம்சங்கள்
Allotment of 10,50,000 equity shares to Manumon Chettiar under the public categoryIssue price fixed at Rs. 25 per share, including a premium of Rs. 15 per shareReceipt of Rs. 1,96,87,500 representing the 75% balance payment for the warrant conversionTotal subscribed share capital increased to 10,36,96,896 equity shares
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive capital infusion that strengthens the balance sheet, despite the marginal equity dilution. Monitor how the company utilizes these funds for its healthcare or IT business segments.
Virinchi to Raise ₹7.83 Cr via Warrant Issue to Promoter in Healthcare Subsidiary
Virinchi Limited is seeking shareholder approval to issue 52.22 lakh convertible equity warrants in its wholly-owned subsidiary, Virinchi Health Care Private Limited, to the company's promoter, Mr. Viswanath Kompella. The warrants are priced at ₹15 each, valuing the healthcare subsidiary at an enterprise value of ₹312.08 crore. Upon conversion, the promoter's stake in the subsidiary will rise to a maximum of 49%, while Virinchi Limited will retain a controlling 51% stake. This move aims to infuse capital into the healthcare arm while maintaining management control by the parent company.
முக்கிய அம்சங்கள்
Issue of 52,22,000 convertible warrants in Virinchi Health Care Private Limited to Promoter Viswanath Kompella.Warrants priced at ₹15 per unit, aggregating to a total investment of approximately ₹7.83 crore.Healthcare subsidiary valued at an enterprise valuation of ₹312.08 crore by an IBBI-registered valuer.Parent company Virinchi Limited to reduce stake from 100% to a minimum of 51% post-conversion.Warrants are convertible within 36 months with 25% of the price payable upfront.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the fairness of the ₹312.08 crore valuation for the healthcare subsidiary and the impact of the parent company's diluted ownership. While the promoter's capital infusion is a sign of commitment, the transition from a 100% subsidiary to a 51% joint-controlled entity is a significant structural change.
Virinchi Promoter to Invest in Subsidiary via 52.22 Lakh Warrants at Rs 15 Each
Virinchi Limited's board has approved a proposal for its promoter, Mr. Viswanath Kompella, to invest in its material subsidiary, Virinchi Health Care Private Limited. The investment involves the issuance of 52,22,000 convertible equity warrants at a price of Rs. 15 per warrant, based on an enterprise valuation of Rs. 312.08 crore for the subsidiary. This transaction will result in the promoter holding up to 49% of the subsidiary's post-issue equity capital. The capital infusion is intended to improve liquidity and strengthen the subsidiary's balance sheet for long-term growth.
முக்கிய அம்சங்கள்
Promoter Mr. Viswanath Kompella to acquire up to 49% stake in material subsidiary Virinchi Health CareIssuance of 52,22,000 convertible equity warrants at Rs. 15 per warrant (FV Rs. 10 + Premium Rs. 5)Subsidiary enterprise valuation pegged at Rs. 312.08 crore by an independent valuerWarrants have a conversion tenure of 36 months from the date of allotmentInvestment aimed at improving liquidity and strengthening the subsidiary's balance sheet
👀 கவனிக்க வேண்டியவை
Investors should view the promoter's direct capital infusion as a sign of confidence in the healthcare vertical, though they should monitor the impact of equity dilution in the subsidiary on consolidated earnings.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
